Verdad Advisers’s Castle Biosciences CSTL Stock Holding History

Verdad Advisers’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,085	Closed	-$276K	–	199
2025 Q4	$276K	Buy	+7,085	New	+$228K	0.32%	80

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verdad Advisers's CSTL Position: Q1 2026 in Review

Verdad Advisers sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 7,085 shares — an estimated $276K sold.

Verdad Advisers first reported a position in CSTL in Q4 2025 and held it in 1 quarter. The position peaked at $276K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

Verdad Advisers reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
Verdad Advisers sold 7,085 Castle Biosciences shares in Q1 2026, an estimated $276K.
Verdad Advisers first reported a position in Castle Biosciences in Q4 2025 and held it in 1 quarter.
Verdad Advisers's Castle Biosciences position peaked at $276K in Q4 2025.
186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.